Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.

Abstract

BACKGROUND:

Based on the results from the ALFA-0701 study, gemtuzumab ozogamicin (GO) has been approved by the European Medicine Agency and by the Italian Drug Agency for the first line treatment of de novo acute-myeloid leukemia (AML). In this analysis, we assessed the cost-effectiveness of GO in combination with daunorubicin and cytarabine (DA), vs DA alone, adopting the perspective of the Italian National Health Service.

METHODS:

For this analysis, a cohort state transition model was developed. The model was designed to capture health states and events that occur throughout the entire disease course and that impact costs and outcomes. The ALFA-0701 study was the main source of clinical data for this analysis. In the model, patients had the same baseline characteristics and experienced the same clinical improvements as in the ALFA-0701 study. Economic data (resource consumption and unit costs) were adapted to reflect expenditure for the Italian National Health Service. Utilities per health state and disutilities due to adverse events were based on the literature and on the general population for those functionally cured. A lifetime horizon was adopted, with both costs and outcome being discounted of 3.0%, annually. Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of results.

RESULTS:

In the base case (lifetime horizon; primary source of data: study ALFA-0701; perspective: Italian National Health Service; discount rate on costs and outcomes: 3.0%), GO + DA was more effective DA both in terms of life-year (LY) survival (6.42 LY vs 5.75 LY, respectively) and quality-of-life adjusted survival (4.69 QALY vs 4.19 QALY, respectively). The overall costs were almost similar in the two groups (slightly lower with GO + DA than with DA; €162,424 and €162,708, respectively). The use of GO increased the costs of drug therapy but saved costs of relapse and costs associated with transplantation (HSCT).

CONCLUSIONS:

If results of the ALFA-0701 study are applied to the Italian healthcare environment, then gemtuzumab ozogamicin, in combination with daunorubicin and cytarabine, would clinical outcomes and reduce lifetime costs, compared with daunorubicin and cytarabine alone for the first line treatment of de novo AML.

TRIAL REGISTRATION:

Not applicable.

• Authors: Roberto Cairoli, Gianluca Furneri, Roberto Di Virgilio, Barbara Veggia, Felicetto Ferrara
• Journal: BMC health services research (BMC Health Serv Res) Vol. 23 Issue 1 Pg. 36 (Jan 16 2023) ISSN: 1472-6963 [Electronic] England
• PMID: 36642712 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• Gemtuzumab
• Daunorubicin
• Cytarabine
• CD33 protein, human
• Sialic Acid Binding Ig-like Lectin 3

Topics

• Humans
• Gemtuzumab (therapeutic use)
• Cost-Effectiveness Analysis
• State Medicine
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Leukemia, Myeloid, Acute (drug therapy, etiology)
• Daunorubicin (therapeutic use)
• Cytarabine (therapeutic use)
• Italy
• Treatment Outcome
• Sialic Acid Binding Ig-like Lectin 3 (therapeutic use)